A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C
A Study of Predictors of the Effectiveness of Pegylated Interferon in a Cohort of Participants With Hepatitis C
This prospective observational study will investigate predictive values of virological
 response in pegylated interferon alfa-2a (Pegasys)/ribavirin (Copegus) treatment-naive
 participants with chronic hepatitis C. Participants will be treated with pegylated interferon
 alfa-2a and ribavirin as prescribed by the physician. Data will be collected for a maximum of
 96 weeks.
Inclusion Criteria:

 - Diagnosis of chronic hepatitis C infection

 Exclusion Criteria:

 -  Co-infection with human immunodeficiency virus (HIV) and/or hepatitis B

 -  Participants previously treated with pegylated interferon alfa-2a/ribavirin

 -  Participation in another clinical study within 30 days prior to study start of ML25544